131 related articles for article (PubMed ID: 10761705)
1. p53 status in multiple human urothelial cancers: assessment for clonality by the yeast p53 functional assay in combination with p53 immunohistochemistry.
Yamamoto S; Tada M; Lee CC; Masuda C; Wanibuchi H; Yoshimura R; Wada S; Yamamoto K; Kishimoto T; Fukushima S
Jpn J Cancer Res; 2000 Feb; 91(2):181-9. PubMed ID: 10761705
[TBL] [Abstract][Full Text] [Related]
2. p53 mutations in multiple urothelial carcinomas: a molecular analysis of the development of multiple carcinomas.
Goto K; Konomoto T; Hayashi K; Kinukawa N; Naito S; Kumazawa J; Tsuneyoshi M
Mod Pathol; 1997 May; 10(5):428-37. PubMed ID: 9160306
[TBL] [Abstract][Full Text] [Related]
3. Clinical evaluation of p53 mutations in urothelial carcinoma by IHC and FASAY.
Watanabe J; Nishiyama H; Okubo K; Takahashi T; Toda Y; Habuchi T; Kakehi Y; Tada M; Ogawa O
Urology; 2004 May; 63(5):989-93. PubMed ID: 15135005
[TBL] [Abstract][Full Text] [Related]
4. Histologic-genetic mapping by allele-specific PCR reveals intraurothelial spread of p53 mutant tumor clones.
Stoehr R; Knuechel R; Boecker J; Blaszyk H; Schmitt R; Filbeck T; Hofstaedter F; Hartmann A
Lab Invest; 2002 Nov; 82(11):1553-61. PubMed ID: 12429815
[TBL] [Abstract][Full Text] [Related]
5. Improved clonality analysis of multifocal bladder tumors by combination of histopathologic organ mapping, loss of heterozygosity, fluorescence in situ hybridization, and p53 analyses.
Denzinger S; Mohren K; Knuechel R; Wild PJ; Burger M; Wieland WF; Hartmann A; Stoehr R
Hum Pathol; 2006 Feb; 37(2):143-51. PubMed ID: 16426913
[TBL] [Abstract][Full Text] [Related]
6. P53 mutations as an identification marker for the clonal origin of bladder tumors and its recurrences.
Dahse R; Gärtner D; Werner W; Schubert J; Junker K
Oncol Rep; 2003; 10(6):2033-7. PubMed ID: 14534739
[TBL] [Abstract][Full Text] [Related]
7. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer.
Esrig D; Spruck CH; Nichols PW; Chaiwun B; Steven K; Groshen S; Chen SC; Skinner DG; Jones PA; Cote RJ
Am J Pathol; 1993 Nov; 143(5):1389-97. PubMed ID: 7901994
[TBL] [Abstract][Full Text] [Related]
8. Immunocytochemical detection of p53 in cultures of exfoliated cells from urine of patients with urothelial cancers.
Okuno H; Kakehi Y; Ogawa O; Yamada H; Ozdemir E; Okada Y; Yoshida O
Jpn J Cancer Res; 1996 Jul; 87(7):718-23. PubMed ID: 8698621
[TBL] [Abstract][Full Text] [Related]
9. Selective detection of inactivating mutations of the tumor suppressor gene p53 in bladder tumors.
Pfister C; Flaman JM; Martin C; Grise P; Frebourg T
J Urol; 1999 Jun; 161(6):1973-5. PubMed ID: 10332483
[TBL] [Abstract][Full Text] [Related]
10. Evidence for oligoclonality and tumor spread by intraluminal seeding in multifocal urothelial carcinomas of the upper and lower urinary tract.
Hafner C; Knuechel R; Zanardo L; Dietmaier W; Blaszyk H; Cheville J; Hofstaedter F; Hartmann A
Oncogene; 2001 Aug; 20(35):4910-5. PubMed ID: 11521204
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of overexpression of p53 tumor suppressor protein in superficial and invasive transitional cell bladder cancer: comparison with DNA ploidy.
Nakopoulou L; Constantinides C; Papandropoulos J; Theodoropoulos G; Tzonou A; Giannopoulos A; Zervas A; Dimopoulos C
Urology; 1995 Sep; 46(3):334-40. PubMed ID: 7660508
[TBL] [Abstract][Full Text] [Related]
12. Comparison of P53 protein overexpression with P53 mutation in bladder cancer: clinical and biologic aspects.
Vet JA; Bringuier PP; Schaafsma HE; Witjes JA; Debruyne FM; Schalken JA
Lab Invest; 1995 Dec; 73(6):837-43. PubMed ID: 8558845
[TBL] [Abstract][Full Text] [Related]
13. P53 point mutations in initial superficial bladder cancer occur only in tumors from current or recent cigarette smokers.
LaRue H; Allard P; Simoneau M; Normand C; Pfister C; Moore L; Meyer F; Têtu B; Fradet Y
Carcinogenesis; 2000 Jan; 21(1):101-6. PubMed ID: 10607740
[TBL] [Abstract][Full Text] [Related]
14. Clonal analysis of bilateral breast cancer.
Shibata A; Tsai YC; Press MF; Henderson BE; Jones PA; Ross RK
Clin Cancer Res; 1996 Apr; 2(4):743-8. PubMed ID: 9816225
[TBL] [Abstract][Full Text] [Related]
15. p53 null phenotype is a "positive result" in urothelial carcinoma in situ.
Sangoi AR; Chan E; Abdulfatah E; Stohr BA; Nguyen J; Trpkov K; Siadat F; Hirsch M; Falzarano S; Udager AM; Kunju LP
Mod Pathol; 2022 Sep; 35(9):1287-1292. PubMed ID: 35322193
[TBL] [Abstract][Full Text] [Related]
16. Metachronous multifocal development of urothelial cancers by intraluminal seeding.
Habuchi T; Takahashi R; Yamada H; Kakehi Y; Sugiyama T; Yoshida O
Lancet; 1993 Oct; 342(8879):1087-8. PubMed ID: 8105314
[TBL] [Abstract][Full Text] [Related]
17. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression.
Sarkis AS; Dalbagni G; Cordon-Cardo C; Zhang ZF; Sheinfeld J; Fair WR; Herr HW; Reuter VE
J Natl Cancer Inst; 1993 Jan; 85(1):53-9. PubMed ID: 7677935
[TBL] [Abstract][Full Text] [Related]
18. Pattern of p53 gene mutations in breast cancers of women of the midwestern United States.
Sommer SS; Cunningham J; McGovern RM; Saitoh S; Schroeder JJ; Wold LE; Kovach JS
J Natl Cancer Inst; 1992 Feb; 84(4):246-52. PubMed ID: 1734086
[TBL] [Abstract][Full Text] [Related]
19. p53 immunohistochemistry in high-grade urothelial carcinoma of the bladder is prognostically significant.
Hodgson A; Xu B; Downes MR
Histopathology; 2017 Aug; 71(2):296-304. PubMed ID: 28342221
[TBL] [Abstract][Full Text] [Related]
20. Molecular evidence supporting field effect in urothelial carcinogenesis.
Jones TD; Wang M; Eble JN; MacLennan GT; Lopez-Beltran A; Zhang S; Cocco A; Cheng L
Clin Cancer Res; 2005 Sep; 11(18):6512-9. PubMed ID: 16166427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
